Sigma Planning’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
C
CM
Sigma Planning's CGTX Position: Q3 2026 in Review
Sigma Planning increased its Cognition Therapeutics (CGTX) stake by 0.69% in Q3 2026, buying an estimated $2.51K and bringing the position to 364,765 shares worth $350K. The position accounts for 0.01% of the portfolio, ranked #995.
Sigma Planning first reported a position in CGTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $431K in Q4 2024. 60 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.
- Sigma Planning held 364,765 shares of Cognition Therapeutics worth $350K as of Q3 2026.
- Sigma Planning bought 2,500 Cognition Therapeutics shares in Q3 2026, an estimated $2.51K.
- Cognition Therapeutics made up 0.01% of Sigma Planning's portfolio in Q3 2026, its #995 holding.
- Sigma Planning first reported a position in Cognition Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Sigma Planning's Cognition Therapeutics position peaked at $431K in Q4 2024.
- 60 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.